Please login to the form below

Not currently logged in
Email:
Password:

breast cancer drug

This page shows the latest breast cancer drug news and features for those working in and with pharma, biotech and healthcare.

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... The validation of our EU marketing application is an important step towards addressing the

Latest news

  • UK approval for Seagen’s oral HER2 inhibitor Tukysa UK approval for Seagen’s oral HER2 inhibitor Tukysa

    MHRA has authorised drug for HER2-positive advanced breast cancer. Seagen’s oral HER2 drug Tukysa has been granted authorisation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ... metastatic breast cancer who have previously

  • EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

    Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... The drug presents a new challenge

  • Immutep slumps on latest efti data in breast cancer Immutep slumps on latest efti data in breast cancer

    down by a third as investors all-but wrote off the drug in breast cancer. ... Immutep certainly isn’t abandoning hope for efti in breast cancer, saying that it is holding on for overall survival data from the study – due in late 2020 – and is still

  • Roche posts minor sales miss in Q4 as biosimilar pressure grows Roche posts minor sales miss in Q4 as biosimilar pressure grows

    Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... More than 5, 500 patients had been prescribed the

More from news
Approximately 0 fully matching, plus 214 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Trastuzumab successfully reduced the aggressiveness of breast cancer cells, helping to improve the lives of those suffering with the condition. ... This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    keep it inhibited – and which also run the risk of cancer cells acquiring resistance by developing receptor mutations. ... this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Moreover, they think there

  • Integrating electronic health records into clinical trials Integrating electronic health records into clinical trials

    At the Leveraging EHR for Clinical Research Now! event, leaders from academia, companies including Amgen and AstraZeneca and the US Food and Drug Administration sought to identify the factors that are ... Pfizer, for example, won an expanded FDA label

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics